C urrent serologic testing for Lyme disease follows a 2-tiered algorithm, an enzyme-linked immunosorbent assay (eLiSA) followed by supplemental Western immunoblots if the first-tier eLiSA is equivocal or positive. 1 We investigated whether a quantitative Lyme eLiSA results by itself could inform clinical decision making, without the need to wait for additional immunoblot results that may take several days. To this end, we performed a crosssectional study of children who had a Lyme eLiSA performed by a single commercial laboratory over a 7-year period and investigated the predictive ability of Lyme eLiSA index values across a range of cutpoints.
C urrent serologic testing for Lyme disease follows a 2-tiered algorithm, an enzyme-linked immunosorbent assay (eLiSA) followed by supplemental Western immunoblots if the first-tier eLiSA is equivocal or positive. 1 We investigated whether a quantitative Lyme eLiSA results by itself could inform clinical decision making, without the need to wait for additional immunoblot results that may take several days. To this end, we performed a crosssectional study of children who had a Lyme eLiSA performed by a single commercial laboratory over a 7-year period and investigated the predictive ability of Lyme eLiSA index values across a range of cutpoints.
MATERIALS AND METHODS

Study Design and Setting
We performed a retrospective cross-sectional study at a single pediatric institution in a Lyme disease endemic area. We included all Lyme eLiSA tests performed between January 1, 2007, and June 30, 2014. The institutional review board approved the study protocol with waiver of informed consent.
Case Identification
We identified all Lyme eLiSA tests performed through an electronic query of the institutional data warehouse. We included all eLiSA test results obtained from children younger than 21 years during the study period. Also, we included multiple test results obtained from the same patient. We selected Lyme eLiSA tests with an index value ≥1.0 (the cutpoint for an equivocal result according to the manufacturer's guidelines) and excluded all positive Lyme eLiSAs without both immunoglobulin G (igG) and immunoglobulin M (igM) Western immunoblots performed from the same serum sample.
Data Collection
for all included Lyme eLiSA tests, we abstracted the following patient-related data from the medical record onto a structured data form: demographics (age and gender), clinical symptoms, erythema migrans (eM) rash diagnosed by the treating clinician, eLiSA index value and immunoblot results. All serologic Lyme disease tests obtained from the study institution were performed at a single commercial reference laboratory (ArUP National Laboratories, Salt Lake, UT, personal communication). This laboratory used the same Lyme eLiSA and Lyme Western blot kits (MarDx, Trinity Biotech, Tray, ireland) throughout the study period. As recommended by the manufacturer, the laboratory converted Lyme eLiSA optical density values to index values by dividing the optical density value by a standardized factor. All specimens with Lyme eLiSA index values ≥1.00 + <1.20 (equivocal) and ≥1.20 (positive) were reflexively evaluated using both igG and igM Western immunoblots. The reference laboratory scored the index values that were evaluated using immunoblots based on the Centers for Disease Control and Prevention criteria. 
Outcome Measure
Our primary outcome was a case of confirmed Lyme disease defined as follows: either a physician-diagnosed eM rash or a positive 2-tiered Lyme serologic test (using criteria specified by the testing laboratory) in a patient with a clinical syndrome compatible with Lyme disease. A positive 2-tiered Lyme serology was defined as a Lyme eLiSA index ≥1.0 with either a positive igG or a positive igM immunoblot. 1 A negative 2-tiered serology was defined as a Lyme index <1.0 or a Lyme index ≥1.0 with negative igG and igM immunoblots. We defined the following as a clinical syndrome consistent with Lyme disease: early (single eM), early disseminated (multiple eM, cranial neuritis, meningitis, carditis) or late disseminated (large joint monoarticular arthritis). 2 Children with nonspecific clinical presentations (eg, fever or fatigue) were considered negative for Lyme disease, even with a positive 2-tiered serology.
Statistical Analysis
We present continuous variables as medians with interquartile range and categorical variables as proportions. We selected the optimum cutpoint for the Lyme eLiSA index value to discriminate Lyme disease from other causes of the patient's clinical findings and then calculated the positive predictive value. All data were analyzed using SPSS version 21.0 (SPSS inc., Chicago, iL).
RESULTS
Of the 7289 Lyme eLiSA tests performed, 1226 (17%) had an index value ≥1.0. Of these, we included the 1215 tests that were performed using supplemental Western blots (99% of those with a positive or equivocal Lyme eLiSA). The median patient age was 10.5 years (interquartile range, 7.1-14.4 years). Lyme disease tests were performed for 87 children (7% of tests sent) with eM rash, 258 (21%) with suspected early disseminated disease, 695 (58%) with suspected late disease and 175 (14%) with nonspecific signs and symptoms.
Six hundred and eighty Lyme eLiSAs (9% of the eLiSAs performed) were obtained from children with Lyme disease. Of these, the diagnosis of Lyme disease was as follows: 32 with eM rash alone, 22 with eM rash and positive 2-tiered Lyme serology increasing the Lyme eLiSA index cutpoint increased the positive predictive value of the eLiSA for the diagnosis of Lyme disease ( 
DISCUSSION
We performed a large cross-sectional study of children from a Lyme endemic region for whom 2-tiered Lyme disease serologic testing was obtained. A higher Lyme eLiSA index value was more strongly predictive of confirmed Lyme disease as conventionally defined. for children with a Lyme eLiSA index value between 1.0 and 2.9 and a clinical presentation compatible with Lyme disease, supplemental Western immunoblot testing should still be performed. However, as nearly all children with compatible clinical syndromes and a Lyme eLiSA index ≥3.0 had Lyme disease, clinicians may be able to make initial clinical management decisions for these children without supplemental immunoblot results.
Clinicians caring for children with possible Lyme disease often need to make initial management decisions before results from 2-tiered Lyme serologic testing are available. Clinical prediction rules can assist decision making by estimating the risk of Lyme disease in children with facial palsy, 3 meningitis 4-6 or arthritis. 7 However, the clinical presentations of Lyme disease and its mimics can overlap considerably. A rapid and accurate first-tier diagnostic test would facilitate early initiation of appropriate therapy while limiting the unnecessary invasive procedures. Antimicrobial therapy active against Borrelia burgdorferi could be promptly initiated for children with confirmed Lyme disease. Perhaps more importantly, in the appropriate clinical scenario, unnecessary invasive procedures such as arthroscopic joint washout for treatment of possible septic arthritis or hospital admission and parenteral antibiotic therapy could potentially be avoided for children with rapidly confirmed Lyme disease. 8 Two-tiered Lyme disease serologic testing combines a sensitive eLiSA with a specific supplemental Western immunoblot. We have demonstrated that, in a Lyme disease endemic area, a very high Lyme eLiSA index value could be used to direct clinical decision making without a confirmatory Western immunoblot. The Lyme eLiSA kit used by our reference laboratory is a moderate complexity diagnostic test that requires approximately 1 hour to obtain results. Although our study institution uses a reference laboratory, many institutions perform a Lyme eLiSA on-site allowing for more rapid access to results. An optimal Lyme disease testing strategy for endemic regions may include a real-time Lyme eLiSA, followed by confirmatory Western immunoblots for low-to-moderately positive Lyme eLiSA tests.
Our study had several important limitations. first, because only Lyme eLiSA tests with an index value ≥1.0 had confirmatory Western blots, we cannot calculate the sensitivity and specificity of the Lyme eLiSA. Second, we studied a single Lyme eLiSA assay with numeric results based on the optical density values, which may not have a linear relationship with B. burgdorferi antibody titer. Therefore, our findings may not hold true for other Lyme eLiSA assays. 9 Third, a positive igM immunoblot may be falsely positive, particularly if the patient's symptoms have been present for more than 1 month. 10 However, when we reclassified children with a positive igM alone with more than 1 month of symptoms as not having Lyme disease, the Lyme eLiSA positive predictive value dropped only slightly (data not shown). fourth, we conducted our study in a Lyme disease endemic area. Children from a geographic area with a lower prevalence of Lyme disease or outside the typical season may require supplemental serologic testing even when the Lyme eLiSA index value is significantly increased.
11,12 finally, we recognize that our findings in a pediatric population may not apply to adult patients.
The burden of Lyme disease continues to increase annually. On the basis of a 2008 survey of 7 large commercial laboratories, investigators estimated an annual incidence of Lyme disease in the hundreds of thousands each year, at a cost of 500 million U.S. dollars for diagnostic testing. 13 Appropriate clinical utilization of 2-tiered Lyme serologic testing, including limiting unnecessary Western immunoblots for children from Lyme disease endemic areas, could limit unnecessary expenditures. Newer serologic assays (eg, Vlse or C6 peptide) seem to have higher sensitivity in early Lyme disease 14 but have not yet been evaluated in children. future evidencebased guidelines will need to provide clinical guidance about the optimal utilization of available Lyme diagnostics. 
